Table 5 Multivariate Cox proportional hazards model to determine predictors of overall survival in patient treated with CDK4/6is plus ET.

From: Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies

Variables

MV-HR

95% CI

P value

Histology (compared to IDC)

 ILC

1.17

0.96–1.41

0.109

 Mixed

0.98

0.62–1.47

0.949

Race (compared to White)

 Black

0.90

0.70–1.15

0.754

 Hispanic

1.08

0.84–1.37

0.504

ET backbone (compared to AI)

 Fulvestrant

1.15

0.99–1.33

0.055

  1. CDK4/6is cyclin-dependent kinase 4 and 6 inhibitors, ET endocrine therapy, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, Mixed mixed invasive ductal and lobular carcinoma, AI aromatase inhibitor, MV-HR multivariate hazard ratio, CI confidence interval.
Back to article page